

MEDICATION COVERAGE POLICY

PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE

POLICY:	Psoriatic Arthritis (PsA)	P&T DATE	6/20/2024
CLASS:	Rheumatology/Immunology Disorders	REVIEW HISTORY	6/23, 7/22, 5/21, 5/20, 5/19, 2/18, 2/17, 2/16, 5/15, 10/14, 2/13, 2/12, 11/12, 5/10, 2/08, 6/08, 2/07
LOB:	MCL		

This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the HPSJ/MVHP Pharmacy and Therapeutic Advisory Committee.

Effective 1/1/2022, the Pharmacy Benefit is regulated by Medi-Cal Rx. Please visit <https://medi-calrx.dhcs.ca.gov/home/> for portal access, formulary details, pharmacy network information, and updates to the pharmacy benefit.

All medical claims require that an NDC is also submitted with the claim. If a physician administered medication has a specific assigned CPT code, that code must be billed with the correlating NDC. If there is not a specific CPT code available for a physician administered medication, the use of unclassified CPT codes is appropriate when billed with the correlating NDC.

OVERVIEW

Psoriatic arthritis (PsA) is an inflammatory condition that usually involves small joints and skin. Individuals with PsA exhibit both arthritis and psoriasis (PsO) symptoms (i.e. joint pain/stiffness, joint swelling, psoriatic plaque development, and/or nail disfiguration). This review will examine the treatment guidelines of PsA, the currently available PsA drug products, and their coverage criteria.

Severe Psoriatic Arthritis*	Severe Psoriasis*
Erosive disease	Psoriasis area & Severity Index (PASI) ≥ 12
Elevated markers of inflammation (ESR, CRP)	Body surface area (BSA) ≥ 10
Long-term damage that interferes with function and causing major impairment in quality of life	Significant involvement in specific areas (e.g. face, hands or feet, nails intertriginous areas, scalp)
Many affected sites including dactylitis, enthesitis	Burden of the disease causing significant disability
Function-limiting PsA at a few sites, rapidly progressive disease	Impairment of physical or mental function and the designation of moderate-to-severe disease despite lower BSA

*The definition of severe PsA and psoriasis as the presence of 1 or more of the items listed. This is not a formal definition. Table adapted from the 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.

The purpose of this coverage policy is to review the available agents (Table 1) and distinguish where the medications may be billed to. For agents listed for coverage under the medical benefit, this coverage is specific to outpatient coverage only (excludes emergency room and inpatient coverage).

Table 1. Available Psoriatic Arthritis Agents (Current as of 4/2023)

CPT Code	Generic Name (Brand Name)	Available Strengths	Pharmacy Benefit	Outpatient Medical Benefit (Restrictions)
Oral DMARDS				
--	Cyclosporine, micronized	25 mg, 100 mg capsule	Yes	No
--	Leflunomide (Arava)	10 mg tablet	Yes	No
J8610 J9260	Methotrexate	2.5 mg tablet 25 mg/2ml vial	Yes	Yes (QL for vials)
--	Sulfasalazine Tablet, DR Tablet	500 mg tablet	Yes	No
PDE4-Inhibitor				
--	Apremilast (Otezla)	30 mg tablet	Yes	No

Biologics				
J0135	Adalimumab (Humira, Humira CF)	20mg/0.4ml, 40mg/0.8ml 40mg/0.4ml	Yes	No
--	Adalimumab (Amjevita)	40 mg/0.8 mL, 20 mg/0.4 mL	Yes	No
J1438	Etanercept (Enbrel)	25mg/ml, 50mg/ml	Yes	No
Q5103	Infliximab-dyyb (Inflectra)	100mg IV vial	Yes	Yes (PA)
Q5104	Infliximab-abda (Renflexis)	100mg IV vial	Yes	Yes (PA)
J1745	Infliximab (Remicade)	100mg IV vial	Yes	Yes (PA)
Q5121	Infliximab-axxq (Avsola)	100mg IV vial	Yes	Yes (PA)
J0129	Abatacept (Orencia)	125mg/ml clickjet; 50mg/0.4mL, 87.5mg/0.7ml, 125mg/ml prefilled syringe; 250mg IV vial	Yes	Yes, for vials (PA)
J0717	Certolizumab (Cimzia)	200mg	Yes	Yes, for lyophilized solutions (PA)
J1602	Golimumab (Simponi)	50mg/4ml IV vial, 100mg/ml, 50mg/0.5ml auto- injector, 50mg/0.5ml 100mg/ml prefilled syringe	Yes	Yes, for vials (PA)
C9166 (for IV only)	Secukinumab (Cosentyx)	125mg/5ml IV vial 150mg/ml auto- injector and pre- filled syringe	Yes	Yes, for vials (PA)
J1628	Guselkumab (Tremfya)	100mg/mL	Yes	No
--	Ixekizumab (Taltz)	80mg/ml	Yes	No
J3357	Ustekinumab (Stelara)	45mg/0.5ml, 90mg/ml	Yes	No
J2327	Risankizumab (Skyrizi)	150mg pre-filled syringe kit 150mg/mL auto- injector	Yes	No
--	Tofacitinib (Xeljanz, Xeljanz XR)	IR: 5mg, XR: 10mg	Yes	No
--	Upadacitinib (Rinvoq)	15mg	Yes	No

EVALUATION CRITERIA FOR APPROVAL/EXCEPTION CONSIDERATION

Below are the coverage criteria and required information for agents with medical benefit restrictions. This coverage criteria has been reviewed and approved by the HPSJ/MVHP Pharmacy & Therapeutics (P&T) Advisory Committee. For agents that do not have established prior authorization criteria, HPSJ/MVHP will make the determination based on Medical Necessity criteria as described in HPSJ/MVHP Medical Review Guidelines (UM06).

DMARDs

Methotrexate 25mg/ml Vial

- Coverage Criteria:** None
- Limits:** Quantity limit 4 units of J9260 METHOTREXATE SODIUM, 50 MG per 28 days.
- Required Information for Approval:** None

Biologics

1st line—Renflexis (infliximab-abda), Inflectra (infliximab-dyyb), Avsola (infliximab-axxq), Remicade (infliximab)

- Coverage Criteria:** Reserved for treatment failure to 12 weeks of dose-optimized, oral DMARD therapy (Methotrexate 15-25mg/week, Cyclosporine, Sulfasalazine, and Leflunomide). If patient is unable to tolerate one oral DMARD, a second oral DMARD must be tried. Must be prescribed by a rheumatologist or dermatologist.
- Limits:** None
- Required Information for Approval:** Clinic notes or prescription history indicating patient has tried at least 12 weeks of dose-optimized oral DMARD (Methotrexate, Cyclosporine, Sulfasalazine, and Leflunomide).

2nd line—Simponi (golimumab), Cimzia (certolizumab)

- Coverage Criteria:** Reserved for treatment failure/documented intolerance to Renflexis, Inflectra, Avsola, or infliximab (Remicade). Must be prescribed by a rheumatologist or dermatologist.
- Limits:** None
- Required Information for Approval:** Prescription history of Renflexis, Inflectra, Avsola, or infliximab (Remicade).

2nd line—Orencia (abatacept)

- Coverage Criteria:** Reserved for treatment failure/documented intolerance to Renflexis, Inflectra, Avsola, or Remicade. Abatacept may be used instead of a TNF-inhibitor in patients with recurrent or serious infections. Must be prescribed by a rheumatologist or dermatologist.
- Limits:** None
- Required Information for Approval:** Prescription history of Renflexis, Inflectra, Avsola, or Remicade OR documented history of recurrent or serious infections.

Cosentyx (secukinumab) IV

- Coverage Criteria:**
 1. Reserved for either
 - (a) treatment failure/documented intolerance to Renflexis, Inflectra, Avsola, or Remicade OR
 - (b) patients with clinically relevant skin involvement defined as either having body surface area >10% or negatively impacting quality of life (such as face or genital involvement) with treatment failure to 12 weeks of dose-optimized oral DMARD therapy (Methotrexate 15-25mg/week, Cyclosporine, Sulfasalazine, and Leflunomide). If patient is unable to tolerate one oral DMARD, a second oral DMARD must be tried.
 2. Must be prescribed by a rheumatologist or dermatologist.
- Limits:** None
- Required Information for Approval:** Prescription history of Renflexis, Inflectra, Avsola, or Remicade OR documented clinically relevant skin involvement with clinic notes or prescription history indicating patient has tried at least 12 weeks of dose-optimized oral DMARD (Methotrexate, Cyclosporine, Sulfasalazine, and Leflunomide).

⊞ **CLINICAL JUSTIFICATION**

Psoriatic Arthritis

2018 The American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) Guideline for the Treatment of Psoriatic Arthritis³⁹

Highlights

- Most recommendations are conditional and applies to the majority of patients but may not be appropriate for all (shared decision-approach).
- Strong recommendations for patients with active PsA and concomitant active inflammatory bowel disease despite treatment with an oral small molecule (e.g. methotrexate)
 - Switch to a TNFi monoclonal antibody biologic over switching to a TNFi biologic soluble receptor biologic (i.e. etanercept).
 - Switch to a TNFi monoclonal antibody over switching to an interleukin (IL)-17 biologic
 - Switch to an IL-12/IL-23i biologic over switching to an IL-17i biologic.
- Other strong recommendations:
 - In adult patients with active PsA and frequent serious infections who are naïve to oral small molecule (OSM) and biologic drugs may start an oral small molecule over a TNFi biologic.
 - Smoking cessation over no smoking cessation.
- Conditional Recommendations
 - Treat-to-target approach for all patients with active PsA.
 - For treatment naïve, active PsA patients- use TNFi biologics as first-line therapy over OSM/DMARDs.
 - OSM drugs may be used instead of a TNFi biologic in patients without severe PsA and without severe psoriasis or in those who prefer an oral drug instead of parenteral therapy, or those with contraindications to TNFi treatment (congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease).
 - For treatment-naïve patients with active PsA, the use of TNFi biologic or OSM is recommended over an interleukin-17.
 - An IL-17i or IL-12/23i may be used instead of TNFi biologics with severe psoriasis or contraindications to TNF biologics.
 - In patients with active PsA despite OSM therapy, switching to a TNFi, IL-17i, or an IL-12/23i biologic is recommended over switching to a different OSM. A different OSM may be used rather than a TNFi, IL17i, or IL-12/23i in patients who prefer an oral medication or those without evidence of severe PsA or severe psoriasis.
 - In patients with active PsA despite TNFi treatment, switching to a different TNFi biologic monotherapy is recommended over switching to IL-12/23i biologic, IL-17i biologic, abatacept, or tofacitinib monotherapy or adding methotrexate to the current TNFi biologic. An IL-12/23i biologic, IL-17i biologic, abatacept, or tofacitinib may be used instead of a different TNFi biologic monotherapy in the case of a primary TNFi biologic failure or serious adverse event to a TNFi.
 - An IL-17i or IL-12/23i biologic may be used instead of a different TNFi biologic, particularly in the presence of severe psoriasis. Abatacept may be used instead of a TNFi biologic in patients with recurrent or serious infections in the absence of severe psoriasis.
 - In treatment-naïve PsA patients with predominant enthesitis, a TNFi biologic is recommended over an OSM as a first-line option.
- The recommendation to use biologics as first-line treatment diverges from recommendations by the European League for Rheumatism (EULAR) for PsA where oral small molecules drugs are recommended as first-line agents for treatment-naïve patients. This was in part due to the lower cost of conventional oral small molecules agents. It should be noted that the recommendation from

the ACR/NPF guidelines to use TNF inhibitors as first-line therapy over OSM/DMARDs is a conditional recommendation due to low to very-low quality of evidence. They do recommend csDMARD's as first line therapy like the EULAR guidelines in specific instances. These instances include if the patient does not have severe PsA, does not have severe psoriasis, prefers oral therapy, has concern over starting a biologic as the first therapy, or has contraindications to TNFi biologics. HPSJ/MVHP will continue to use oral small molecule drugs as first-line agents from a cost-effective standpoint. The 2018 ACR/NPF guidelines also use data that is more outdated than that of the new 2023 EULAR guidelines.

The 2023 EULAR PsA Guidelines⁴⁶ recommends the following:


Table 2

2023 updated EULAR recommendations for the pharmacological management of psoriatic arthritis

	Level of agreement, mean (SD)
Overarching principles	
A Psoriatic arthritis is a heterogeneous and potentially severe disease, which may require multidisciplinary treatment.	10.0 (0.1)
B Treatment of psoriatic arthritis patients should aim at the best care and must be based on a shared decision between the patient and the rheumatologist, considering efficacy, safety, patient preferences and costs.	9.7 (0.6)
C Rheumatologists are the specialists who should primarily care for the musculoskeletal manifestations of patients with psoriatic arthritis; in the presence of clinically relevant skin involvement, a rheumatologist and a dermatologist should collaborate in diagnosis and management.	9.7 (0.5)
D The primary goal of treating patients with psoriatic arthritis is to maximise health-related quality of life, through control of symptoms, prevention of structural damage, normalisation of function and social participation; abrogation of inflammation is an important component to achieve these goals.	9.9 (0.3)
E In managing patients with psoriatic arthritis, consideration should be given to each musculoskeletal manifestation and treatment decisions made accordingly.	9.8 (0.4)
F When managing patients with psoriatic arthritis, non-musculoskeletal manifestations (particularly skin, eye and gastrointestinal tract) should be taken into account; comorbidities such as obesity, metabolic syndrome, cardiovascular disease or depression should also be considered.	9.7 (0.7)
G The choice of treatment should take account of safety considerations regarding individual modes of action to optimise the benefit–risk profile.	9.9 (0.4)

Recommendations	Level of evidence	Grade of recommendation	Level of agreement, mean (SD)
1 Treatment should be aimed at reaching the target of remission or, alternatively, low disease activity, by regular disease activity assessment and appropriate adjustment of therapy.	1b	A	9.5 (1.0)
2 Non-steroidal anti-inflammatory drugs may be used to relieve musculoskeletal signs and symptoms ^a ; local injections of glucocorticoids may be considered as adjunctive therapy ^b .	1b ^a , 3b ^b	A ^a , C ^b	9.5 (0.7)
3 In patients with polyarthritis, or those with monoarthritis/oligoarthritis and poor prognostic factors ^a (eg, structural damage, elevated acute phase reactants, dactylitis or nail involvement), a csDMARD should be initiated rapidly, with methotrexate preferred in those with clinically relevant skin involvement.	1b, 4 ^a	B, C ^a	9.3 (0.8)
4 In patients with peripheral arthritis and an inadequate response to at least one csDMARD, therapy with a bDMARD should be commenced.	1a	A	9.5 (1.3)
5 In patients with peripheral arthritis and an inadequate response to at least one bDMARD, or when a bDMARD is not appropriate ^a , a JAKi may be considered, taking safety considerations* into account.	1b, 4 ^a	B, D ^a	9.1 (1.5)
6 In patients with mild disease and an inadequate response to at least one csDMARD, in whom neither a bDMARD nor a JAKi* is appropriate, a PDE4 inhibitor may be considered.	1b	B	8.7 (1.1)
7 In patients with unequivocal enthesitis and an insufficient response to NSAIDs or local glucocorticoid injections, therapy with a bDMARD should be considered.	1b	B	9.5 (0.9)
8 In patients with clinically relevant axial disease with an insufficient response to NSAIDs, therapy with an IL-17A inhibitor, a TNF inhibitor, an IL-17 A/F inhibitor or a JAKi* should be considered.	1b	B	9.4 (1.3)
9 The choice of the mode of action should reflect non-musculoskeletal manifestations related to psoriatic arthritis; with clinically relevant skin involvement, preference should be given to an IL-17A or IL-17A/F or IL-23 or IL-12/23 inhibitor; with uveitis to an anti-TNF monoclonal antibody; and with IBD to an anti-TNF monoclonal antibody or an IL-23 inhibitor or IL-12/23 inhibitor or a JAKi*.	1b	B	9.6 (0.7)
10 In patients with an inadequate response or intolerance to a bDMARD or a JAKi, switching to another bDMARD or JAKi* should be considered ^a , including one switch within a class ^b .	1b ^a , 4 ^b	C	9.5 (0.7)
11 In patients in sustained remission, tapering of DMARDs may be considered.	2b	B	9.4 (1.2)

- 'Mild disease' is defined as oligoarticular or enthesal disease without poor prognostic factors and limited skin involvement.
- csDMARDs (conventional synthetic DMARDs) include methotrexate, sulfasalazine or leflunomide. bDMARDs (biologic DMARDs) here include TNF inhibitors (both original and biosimilars), drugs targeting the IL-17 and IL-12–23/IL-23-p19 pathways, and in the context of recommendation 10 also CTLA4 (cytotoxic T-lymphocyte–associated antigen 4) inhibition. JAKis (Januse kinase inhibitors) include tofacitinib and upadacitinib.
- The superscript letters 'a' and 'b' are used to link a part of the recommendation to a level of evidence.
- The table shows the level of evidence, grade of recommendation and level of agreement among taskforce members (0–10 scale).
- *For JAKis, caution is needed for patients aged 65 years or above, those who are current or past long-time smokers, with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors or with other malignancy risk factors, and with known risk factors for venous thromboembolism.
- bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; CTLA4, cytotoxic T-lymphocyte–associated antigen 4; DMARDs, disease-modifying antirheumatic drugs; IBD, inflammatory bowel disease; IL, interleukin; JAKi, Janus kinase inhibitor; NSAIDs, non-steroidal anti-inflammatory drugs; PDE4, phosphodiesterase 4; TNF, tumour necrosis factor.



1. Some studies suggest that enthesitis may respond to methotrexate, but the level of evidence is low.

2. No glucocorticoids for axial disease.

3. The target is remission or low disease activity (especially with long standing disease) in accordance with the treat-to-target recommendations.

4. Preferred in the presence of relevant skin involvement, however in case of concomitant inflammatory bowel disease or uveitis, a TNF monoclonal antibody or (for IBD) IL-23i or 12/23i or JAKi is recommended.

5. Improvement means at least 50% reduction in disease activity.

6. Arthritis/enthesitis: TNFi or IL-17i or IL-12/23i or IL-23p19i; Skin: IL-17i or IL-12/23i or IL-23p19i; Uveitis:

anti-TNF monoclonal antibody; IBD: anti-TNF monoclonal antibody or IL-12/23i or IL-23p19i or JAKi; Consider using PDE4i in mild disease if bDMARD and JAKi is inappropriate.

7. For JAK-inhibitors, caution is needed for patients aged 65 years or above, current or past long-time smokers, with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors or with other malignancy risk factors; with known risk factors for venous thromboembolism.

8. Consider tapering in sustained remission.

9. Including abatacept.

Highlights

- The 2023 EULAR Guidelines recommend a “treat-to-target” approach for PsA.
 - Patients with active disease should be monitored every 3 months and treatment should be adjusted when appropriate. The TICOPA trial demonstrated patients who had treatment escalation from DMARD therapy to biologics had better therapeutic outcomes when they were monitored and the treatment regimen was adjusted more vigorously.³
- In patients with polyarthritis, or those with monoarthritis/oligoarthritis and poor prognostic factors (eg, structural damage, elevated acute phase reactants, dactylitis or nail involvement), a csDMARD should be initiated rapidly, with methotrexate preferred in those with clinically relevant skin involvement.
- In patients with peripheral arthritis and an inadequate response to at least one csDMARD, therapy with a bDMARD should be commenced.
- In patients with peripheral arthritis and an inadequate response to at least one bDMARD, or when a bDMARD is not appropriate, a JAKi may be considered, taking safety considerations into account.
- In patients with mild disease and an inadequate response to at least one csDMARD, in whom neither a bDMARD nor a JAK inhibitor is appropriate, a PDE4 inhibitor may be considered.
- In patients with clinically relevant axial disease with an insufficient response to NSAIDs, therapy with an IL-17Ai, a TNFi, an IL-17 A/Fi or a JAKi should be considered.
- The choice of the mode of action should reflect non-musculoskeletal manifestations related to psoriatic arthritis; with clinically relevant skin involvement, preference should be given to an IL-17A or IL-17A/F or IL-23 or IL-12/23 inhibitor; with uveitis to an anti-TNF monoclonal antibody; and with IBD to an anti-TNF monoclonal antibody or an IL-23i or IL-12/23i or a JAKi.
- In patients with an inadequate response or intolerance to a bDMARD or a JAKi, switching to another bDMARD or JAKi should be considered, including one switch within a class.

The 2023 EULAR guidelines recommend for patients with polyarthritis that a csDMARD (methotrexate, sulfasalazine, or leflunomide) is initiated first. Only in patients with an inadequate response to at least one csDMARD do they recommend therapy with a bDMARD instead. Therefore, our HPSJ/MVHP criteria generally requires initiating therapy with oral DMARDs prior to biologics and allowing some exceptions upon review. Efficacy between biologics is analyzed and cost may vary due to differences in administration frequency (twice monthly vs. weekly vs. monthly, and so forth). The new guidelines also prefer biologics with different modes of action for patients with certain non-musculoskeletal manifestations. Therefore, HPSJ/MVHP’s order of preference of the biologic therapies are based on efficacy and costs.

Role of oral agents (DMARDs and immunosuppressants)

Oral DMARDs are commonly used as first-line therapies in many mild-moderate inflammatory disorders with a few exceptions (e.g. Ankylosing Spondylitis). For most patients, treatment with oral agents may be sufficient for their condition. Generally, 12 weeks of continuous DMARD therapy is considered to be an adequate trial—assuming the drug is adequately dosed. In patients with liver and/or renal impairment, DMARDs are not necessarily excluded right away. In most cases, DMARDs can be safely used as long as there is regular monitoring of labs and side effects and the dosing is adjusted accordingly.

Table 1: Commonly used oral agents in chronic inflammatory diseases

Oral Agent	Joint	Skin	GI	liver damage	kidney damage	Pregnancy	Breastfeeding
Azathioprine	X	X*	X	monitor	monitor & dose adjust	Avoid use	Not recommended
Cyclosporine	X*	X	X*	monitor	monitor & dose adjust	Avoid use	Not recommended
Leflunomide	X	X	X*	avoid use	avoid use	Contraindicated	Unknown
Mercaptopurine	X*	X*	X	monitor	monitor & dose adjust	Avoid use	Unknown

Methotrexate	X	X	X	avoid use	monitor & dose adjust	Contraindicated	Contraindicated
Sulfasalazine	X	X*	X	monitor	monitor	Generally safe	Generally safe
<i>*limited evidence</i>							

Special Populations

Pregnancy

Guidelines for pregnancy, as stated by the Canadian guidelines and the American National Psoriasis Foundation, indicate that 1st line therapy includes low- to moderate potency corticosteroids, 2nd line therapy includes narrow band UVB, and 3rd line therapy, only to be used if benefits outweigh risks, includes cyclosporine or TNF inhibitors.²⁰⁻²¹ Other DMARDs deemed safe include sulfasalazine and azathioprine, and possibly leflunomide.²² Azathioprine has a risk for premature births and, although limited animal data contraindicates its use, leflunomide has an apparently low human teratogenicity risk. Cyclosporine and sulfasalazine seem to be the safest or most preferred DMARD agents.²²

Elevated LFTs

Specific guidelines for patients who have elevated LFTs are not available, but the American Academy of Dermatology guidelines do have suggestions for LFT monitoring and some recommendations on protocol if LFTs are elevated to a certain level. For methotrexate, if elevation exceeds 2x normal levels, LFT monitoring must be checked more frequently; if elevation exceeds 3x normal levels, consider dose reduction (administer 75% of dose); if elevation exceeds 5x normal, discontinuation of the medication is recommended. No other drugs have specific guidelines for LFT levels.²³ The 2008 ACR guidelines state that leflunomide, methotrexate, and sulfasalazine should not be started nor resumed if liver transaminases were >2x the upper normal limit. Despite this, there are no recommendations on discontinuation.²⁴ A paper regarding expert opinion on the treatment of psoriasis in special circumstances speaks to the use of biologics in the setting of fatty liver disease. The panel considered etanercept and ustekizumab to be the best options for use in a patient with fatty liver disease.²⁵

REFERENCES

1. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis*. 2015; doi:10.1136/annrheumdis-2015-208337.
2. Singh JA, Saag KG, Bridges JR L, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care & Research*. 2015; DOI 10.1002/acr.22783.
3. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomized controlled trial. *Lancet* 2015 doi: 10.1016/S0140-6736(15)00347-5.
4. Schmitt J, Rosumeck S, Thomaschewski G, et al. Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. *Br J Dermatol* 2014;170:274–303.
5. Coates LC, Tillet W, Chandler D, et al. The 2012 BSA and BHPR guideline for the treatment of psoriatic arthritis with biologics. *Rheumatology*. 2013. doi: 10.1093/rheumatology/ket187.
6. Gottlieb A, Korman N, Gordon K, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2—Psoriatic Arthritis: Overview and guidelines of care for treatment with an emphasis on biologics. *J Am Acad Dermatol*. 2008; 58: 851-64.
7. Ramiro S, Smolen SJ, Landewe Ro, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis*. December 2015. doi:10.1136/annrheumdis-2015-208466.
8. Yoo DH, Racewicz A, Brzezicki J, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. *Arthritis Res Ther* 2016;18:82.

9. ClinicalTrials.Gov. Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis. October 23, 2016.
<https://clinicaltrials.gov/ct2/show/NCT01970475>. Accessed January 22, 2017.
10. Griffiths CE, et al. The EGALITY study: A confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis. *Br J Dermatol*. 2016 Oct 27. doi: 10.1111/bjd.15152.
11. Dapavo P, et al. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. *Journal of American Academy of Dermatology*. 2016 Oct;75(4):736-9.
12. FIMEA. Interchangeability of Biosimilars—Position of Finnish Medicines Agency Fimea. May 22, 2015.
http://www.fimea.fi/instancedata/prime_product_julkaisu/fimea/embeds/fimeawwwstructure/29197_Biosimilaarien_vaihtokelpoisuus_EN.pdf. Accessed January 22, 2017.
13. FDA. Summary Minutes of the Arthritis Advisory Committee Meeting, July 12, 2016.
<http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM520027.pdf>. Accessed January 21, 2017.
14. Dörner T, Strand V, Cornes P, et al. The changing landscape of biosimilars in rheumatology. *Ann Rheum Dis* 2016; 75:974–82. doi:10.1136/annrheumdis-2016-209166
15. FDA. Biosimilars: Questions and Answers Regarding implementation of Biologics Price Competition and Innovation Act of 2009. April 2015.
<http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.pdf>. Accessed January 21, 2017
16. Dapavo P, et al. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. *Journal of American Academy of Dermatology*. 2016 Oct;75(4):736-9
17. Results from the NOR-SWITCH study support switch from Remicade to Remsima (biosimilar infliximab). Mundipharma. 19 October 2016. <http://www.mundipharma.com/docs/default-source/default-document-library/161019-ueg-press-release-final.pdf?sfvrsn=0>. Accessed 2 Feb 2017.
18. Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. *N Engl J Med*. 2015;373(14):1329-39.
19. McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2015;386(9999):1137-46.
20. Canadian Psoriasis Guidelines Addendum Committee. 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009. *J Cutan Med Surg*. 2016 Sep;20(5):375-431.
21. Bangsgaard N, et al. Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. *Am J Clin Dermatol*. 2015. 16:389-398.
22. Kurizky PS, et al. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding. *An Bras Dermatol*. 2015;90(3):367-75.
23. Menter A, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. 2009 Sep; 61(3): 451-485.
24. Saag KG, et al. American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. 2008 Jun 15; 59(6):762-784.
25. Carrascosa JM, et al. Expert Recommendations on Treating Psoriasis in Special Circumstances. 2015 April. 106(4):292-309.
26. San Joaquin County. United States Census Bureau website.
<https://www.census.gov/quickfacts/sanjoaquincountycalifornia>. Updated 2019. Accessed May 4th, 2022.

27. Stanislaus County. United States Census Bureau website. <https://www.census.gov/quickfacts/fact/table/stanislauscountycalifornia/PST045221>. Updated 2019. Accessed May 4th, 2022.
28. Health Plan of San Joaquin. *Medication Coverage Policy Psoriasis*. French Camp, CA: Health Plan of San Joaquin; 2022.
29. Body Measurements. Centers for Disease Control and Prevention website. <https://www.cdc.gov/nchs/fastats/body-measurements.htm>. Updated September 10, 2021. Accessed May 4th, 2022.
30. Soltani-Arabshahi R, Wong B, Feng BJ, Goldgar DE, Duffin KC, Krueger GG. Obesity in early adulthood as a risk factor for psoriatic arthritis. *Arch Dermatol*. 2010;146(7):721-726.
31. Obesity and Socioeconomic Status in Adults. Centers for Disease Control and Prevention website. <https://www.cdc.gov/nchs/products/databriefs/db50.htm>. Updated November 6, 2015. Accessed May 5th, 2022.
32. Rodgers M, Epstein D, Bojke L, et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. *Health Technology Assessment*. 2011; 15(10). DOI: 10.3310/hta15100.
33. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). *Ann Rheum Dis*. 2014; 73(1): 48-55.
34. Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic and safety results from a phase III, randomized, placebo-controlled trial. *Arthritis Rheum*. 2012; 64(8): 2504-17.
35. Ramiro S, Smolen SJ, Landewe Ro, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis*. December 2015. doi:10.1136/annrheumdis-2015-208466.
36. Prescribing information: Orenzia®. Princeton, NJ; Bristol-Meyers Squibb Company.
37. van der Heijde D, Gladman DD, Kishimoto M, et al. Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1) [published online December 15, 2017]. *J Rheumatol*. doi:10.3899/jrheum.170429
38. Prescribing information: Taltz. Indianapolis, Indiana; Eli Lilly and Company
39. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis Rheumatol*. 2018; 71 (1): 5-32.
40. Prescribing information: Xeljanz and Xeljanz XR® NY, NY; Pfizer Labs.
41. Mease P, Hall S, FitzGerald O, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. *N Engl J Med*. 2017; 377:1537-1550.
42. Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. *N Engl J Med*. 2017; 377: 1525-1536.
43. ClinicalTrials.gov [Internet]. Identifier: NCT01976364, Open-Label Extension Study of Tofacitinib in Psoriatic Arthritis. Available from: <https://clinicaltrials.gov/ct2/show/NCT01976364>.
44. Deodhar A, Helliwell PS, Boehncke W-H, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNF α inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. *Lancet*. 2020;395(10230):1115-1125.
45. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naïve patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. *Lancet*. 2020;395(10230):1126-1136.
46. Gossec L, Kerschbaumer A, Ferreira RJO, et al EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. *Annals of the Rheumatic Diseases* Published Online First: 18 March 2024. doi: 10.1136/ard-2024-225531.

47. Smolen J, Siebert S, Korotaeva T, et al. Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results. *Ann Rheum Dis.* 2021;80(11):1419-1428.
48. Mease P, Gottlieb A, Van Der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomized, double-blind, placebo-controlled, phase III study in psoriatic arthritis. *Ann Rheum Dis.* 2017;76(9):1550-1558.
49. Mease P, McInnes I, Tam L, et al. Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis. *Rheumatology (Oxford, England).* 2021;60(50):2109-2121.
50. Prescribing information: Cosentyx®. East Hanover, NJ; Novartis Pharmaceuticals Corporation.
51. Novartis Pharmaceuticals Corporation. Psoriatic Arthritis Treatment Results | COSENTYX® (secukinumab). www.cosentyx.com. Accessed April 25, 2024. <https://www.cosentyx.com/psoriatic-arthritis/treatment-results>
52. Sbidian E, Le Cleach L, Trinquart L, et al. Systemic pharmacological treatments for chronic plaque psoriasis. Cochrane Skin Group, ed. Cochrane Database of Systematic Reviews. Published online July 12, 2023. Doi: 10.1002/14651858.CD011535.pub6
53. A.B. Gottlieb, J.F. Merola, K. Reich, F. Behrens, P. Nash, C.E.M. Griffiths, W. Bao, P. Pellet, L. Pricop, I.B. McInnes, Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study, *British Journal of Dermatology*, Volume 185, Issue 6, 1 December 2021, Pages 1124–1134, <https://doi.org/10.1111/bjd.20413>

REVIEW & EDIT HISTORY

Document Changes	Reference	Date	P&T Chairman
Creation of Policy	Psoriasis - biologicals 2-20-07.doc	2/2007	Allen Shek, PharmD
Updated Policy	Biological Response Modifiers Review 2-19-08.doc	2/2008	Allen Shek, PharmD
Updated Policy	HPA Suppression among Medium Potency Topical Corticosteroids.doc	6/2008	Allen Shek, PharmD
Updated Policy	Biologic Response Modifiers 2010 final.docx	5/2010	Allen Shek, PharmD
Updated Policy	TNF MUE summary 2-21-2012.docx	2/2012	Allen Shek, PharmD
Updated Policy	Calcipotriene.docx	11/2012	Allen Shek, PharmD
Updated Policy	Biologic Response Modifiers for Psoriasis 2013-2-19.docx	2/2013	Allen Shek, PharmD
Updated Policy	Psoriatic Arthritis & Ankylosing Spondylitis.docx	10/2014	Jonathan Szkotak, PharmD
Updated Policy	Class Review of Topical & Systemic Agents Used for Skin Inflammation Disorders with an Emphasis on Psoriasis.docx	5/2015	Jonathan Szkotak, PharmD
Updated Policy	HPSJ Coverage Policy – Rheum & immuno – Psoriatic Arthritis 2015-05.docx	9/2015	Jonathan Szkotak, PharmD
Updated Policy	Class Review- Biologics, Apremilast, and Tofacitinib in Inflammatory Joint, Skin, and Bowel Diseases.docx	2/2016	Johnathan Yeh, PharmD
Updated Policy	HPSJ Coverage Policy - Rheum & Immuno - Psoriatic Arthritis 2017-02.docx	2/2017	Johnathan Yeh, PharmD
Updated Policy	HPSJ Coverage Policy - Rheum & Immuno - Psoriatic Arthritis 2018-02.docx	02/2018	Johnathan Yeh, PharmD
Updated Policy	HPSJ Coverage Policy - Rheum & Immuno - Psoriatic Arthritis 2019-05.docx	05/2019	Matthew Garrett, PharmD
Updated Policy	Psoriatic Arthritis 2020-05.docx	05/2020	Matthew Garrett, PharmD

Updated Policy	Psoriatic Arthritis.docx	05/2021	Matthew Garrett, PharmD
Updated Policy	Psoriatic Arthritis.docx	07/2022	Matthew Garrett, PharmD
Updated Policy	Psoriatic Arthritis.docx	06/2023	Matthew Garrett, PharmD
Updated Policy	Psoriatic Arthritis.docx	06/2024	Matthew Garrett, PharmD

Note: All changes are approved by the HPSJ/MVHP P&T Committee before incorporation into the utilization policy.